Company information
- Ticker
- 4771
- Country
- Taiwan
- Sector
- Health Care
- Industry
- Biotech
VF Business Summary
Vision Focus (4771.TW) operates as a leading Original Design Manufacturer (ODM) and Original Equipment Manufacturer (OEM) specializing in the research, development, and high-volume production of soft contact lenses. The company generates revenue primarily through the manufacturing and sale of disposable hydrogel and silicone hydrogel lenses, with a product portfolio encompassing clear, cosmetic color, and functional lenses such as toric and multifocal designs. Its business is strategically segmented by geography, with the China and Japan markets serving as its primary revenue drivers, complemented by an expanding footprint in the United States following key FDA approvals for its silicone hydrogel products. Within the competitive landscape, Vision Focus contends with major Taiwanese peers such as St. Shine Optical (1565.TW), Pegavision (6491.TW), and Visco Vision (6782.TW). The company distinguishes itself through its rapid product iteration cycles and advanced automated manufacturing processes, positioning it as a high-growth, technology-forward challenger to traditional incumbents in the global optical market. The company’s leadership is anchored by Chairman Huang Xiu-quan and General Manager (CEO) Shi An (Angus Shih), who both bring extensive experience in precision manufacturing and industrial scaling. Shi An, who holds a Ph.D. and has a background in high-tech R&D, has been instrumental in integrating automated optical inspection (AOI) and advanced material science into the company's production lines to ensure high yield rates and product consistency. Vision Focus was established with significant strategic backing from the Chang Wah Group, specifically through Chang Wah Electromaterials (8070.TW), which remains a cornerstone institutional investor and provides a robust supply chain foundation. The board of directors, which includes representatives from the Chang Wah Group, oversees a strategy focused on aggressive R&D investment and the expansion of manufacturing capacity, including the 2026 commissioning of new facilities to meet surging global demand for high-margin silicone hydrogel lenses.